JP2009523436A - アスベスト被曝に関連した肺癌を同定する方法 - Google Patents
アスベスト被曝に関連した肺癌を同定する方法 Download PDFInfo
- Publication number
- JP2009523436A JP2009523436A JP2008550791A JP2008550791A JP2009523436A JP 2009523436 A JP2009523436 A JP 2009523436A JP 2008550791 A JP2008550791 A JP 2008550791A JP 2008550791 A JP2008550791 A JP 2008550791A JP 2009523436 A JP2009523436 A JP 2009523436A
- Authority
- JP
- Japan
- Prior art keywords
- lung cancer
- asbestos
- exposed
- expression
- gene
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Withdrawn
Links
- 238000000034 method Methods 0.000 title claims abstract description 111
- 208000020816 lung neoplasm Diseases 0.000 title claims abstract description 91
- 201000005202 lung cancer Diseases 0.000 title claims abstract description 87
- 206010058467 Lung neoplasm malignant Diseases 0.000 title claims abstract description 86
- 206010063599 Exposure to chemical pollution Diseases 0.000 title claims abstract description 46
- 230000002759 chromosomal effect Effects 0.000 claims abstract description 32
- 108700028369 Alleles Proteins 0.000 claims abstract description 31
- 230000014509 gene expression Effects 0.000 claims description 243
- 108090000623 proteins and genes Proteins 0.000 claims description 187
- 239000000523 sample Substances 0.000 claims description 139
- 206010028980 Neoplasm Diseases 0.000 claims description 105
- 238000004458 analytical method Methods 0.000 claims description 56
- 201000011510 cancer Diseases 0.000 claims description 17
- 108091092878 Microsatellite Proteins 0.000 claims description 15
- 230000008859 change Effects 0.000 claims description 8
- 239000012472 biological sample Substances 0.000 claims description 5
- 210000004369 blood Anatomy 0.000 claims description 4
- 239000008280 blood Substances 0.000 claims description 4
- 238000007901 in situ hybridization Methods 0.000 claims description 4
- 238000001001 laser micro-dissection Methods 0.000 claims description 3
- 206010036790 Productive cough Diseases 0.000 claims description 2
- 230000036210 malignancy Effects 0.000 claims description 2
- 210000002966 serum Anatomy 0.000 claims description 2
- 208000024794 sputum Diseases 0.000 claims description 2
- 210000003802 sputum Anatomy 0.000 claims description 2
- 239000010425 asbestos Substances 0.000 abstract description 96
- 229910052895 riebeckite Inorganic materials 0.000 abstract description 96
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract description 13
- 201000010099 disease Diseases 0.000 abstract description 12
- 150000007523 nucleic acids Chemical class 0.000 description 108
- 102000039446 nucleic acids Human genes 0.000 description 103
- 108020004707 nucleic acids Proteins 0.000 description 103
- 210000004027 cell Anatomy 0.000 description 88
- 238000012360 testing method Methods 0.000 description 40
- 210000001519 tissue Anatomy 0.000 description 39
- 102000004169 proteins and genes Human genes 0.000 description 37
- 210000004072 lung Anatomy 0.000 description 35
- 210000000349 chromosome Anatomy 0.000 description 34
- 238000009396 hybridization Methods 0.000 description 32
- 230000003321 amplification Effects 0.000 description 31
- 238000003199 nucleic acid amplification method Methods 0.000 description 31
- 239000003550 marker Substances 0.000 description 30
- 230000000295 complement effect Effects 0.000 description 27
- 230000005856 abnormality Effects 0.000 description 26
- 239000012634 fragment Substances 0.000 description 26
- 239000000835 fiber Substances 0.000 description 21
- 150000001413 amino acids Chemical class 0.000 description 19
- 150000001875 compounds Chemical class 0.000 description 19
- 208000037841 lung tumor Diseases 0.000 description 19
- 239000002773 nucleotide Substances 0.000 description 19
- 125000003729 nucleotide group Chemical group 0.000 description 19
- 102000040430 polynucleotide Human genes 0.000 description 18
- 108091033319 polynucleotide Proteins 0.000 description 18
- 239000002157 polynucleotide Substances 0.000 description 18
- 108091032973 (ribonucleotides)n+m Proteins 0.000 description 17
- 208000032818 Microsatellite Instability Diseases 0.000 description 17
- 238000004422 calculation algorithm Methods 0.000 description 17
- 108090000765 processed proteins & peptides Proteins 0.000 description 17
- 201000004656 asbestos-related lung carcinoma Diseases 0.000 description 16
- 102000004196 processed proteins & peptides Human genes 0.000 description 16
- 229920001184 polypeptide Polymers 0.000 description 15
- 230000000694 effects Effects 0.000 description 14
- 239000000047 product Substances 0.000 description 14
- 238000003491 array Methods 0.000 description 13
- 238000005259 measurement Methods 0.000 description 13
- 238000012216 screening Methods 0.000 description 13
- 238000003786 synthesis reaction Methods 0.000 description 13
- 239000013610 patient sample Substances 0.000 description 12
- 238000003752 polymerase chain reaction Methods 0.000 description 12
- 238000001514 detection method Methods 0.000 description 11
- 238000012217 deletion Methods 0.000 description 10
- 230000037430 deletion Effects 0.000 description 10
- 239000000463 material Substances 0.000 description 10
- 108091028043 Nucleic acid sequence Proteins 0.000 description 9
- 238000003556 assay Methods 0.000 description 9
- 230000035772 mutation Effects 0.000 description 9
- 208000009956 adenocarcinoma Diseases 0.000 description 8
- 238000009739 binding Methods 0.000 description 8
- 230000015572 biosynthetic process Effects 0.000 description 8
- 239000003153 chemical reaction reagent Substances 0.000 description 8
- 239000002299 complementary DNA Substances 0.000 description 8
- 229940079593 drug Drugs 0.000 description 8
- 239000003814 drug Substances 0.000 description 8
- 230000001105 regulatory effect Effects 0.000 description 8
- 238000006467 substitution reaction Methods 0.000 description 8
- 241000282414 Homo sapiens Species 0.000 description 7
- 230000027455 binding Effects 0.000 description 7
- 238000007405 data analysis Methods 0.000 description 7
- 230000008034 disappearance Effects 0.000 description 7
- 238000005516 engineering process Methods 0.000 description 7
- 108020004999 messenger RNA Proteins 0.000 description 7
- 238000010606 normalization Methods 0.000 description 7
- 238000002360 preparation method Methods 0.000 description 7
- 108020004705 Codon Proteins 0.000 description 6
- 238000013459 approach Methods 0.000 description 6
- 230000000391 smoking effect Effects 0.000 description 6
- 206010041823 squamous cell carcinoma Diseases 0.000 description 6
- 239000013614 RNA sample Substances 0.000 description 5
- 230000009286 beneficial effect Effects 0.000 description 5
- 239000013068 control sample Substances 0.000 description 5
- 238000013461 design Methods 0.000 description 5
- 238000002405 diagnostic procedure Methods 0.000 description 5
- 230000036541 health Effects 0.000 description 5
- 238000003018 immunoassay Methods 0.000 description 5
- 239000000203 mixture Substances 0.000 description 5
- 238000011002 quantification Methods 0.000 description 5
- 238000011160 research Methods 0.000 description 5
- 239000000126 substance Substances 0.000 description 5
- 238000013518 transcription Methods 0.000 description 5
- 230000035897 transcription Effects 0.000 description 5
- 238000011282 treatment Methods 0.000 description 5
- 241000945470 Arcturus Species 0.000 description 4
- 206010027406 Mesothelioma Diseases 0.000 description 4
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 4
- 230000002159 abnormal effect Effects 0.000 description 4
- 238000006243 chemical reaction Methods 0.000 description 4
- 238000010367 cloning Methods 0.000 description 4
- 230000002950 deficient Effects 0.000 description 4
- 230000018109 developmental process Effects 0.000 description 4
- 238000009826 distribution Methods 0.000 description 4
- 229940000406 drug candidate Drugs 0.000 description 4
- 230000006870 function Effects 0.000 description 4
- 230000002068 genetic effect Effects 0.000 description 4
- 238000000370 laser capture micro-dissection Methods 0.000 description 4
- 230000001404 mediated effect Effects 0.000 description 4
- 238000001531 micro-dissection Methods 0.000 description 4
- 238000002493 microarray Methods 0.000 description 4
- 238000012544 monitoring process Methods 0.000 description 4
- 229920000642 polymer Polymers 0.000 description 4
- 230000002265 prevention Effects 0.000 description 4
- 238000012545 processing Methods 0.000 description 4
- 239000003642 reactive oxygen metabolite Substances 0.000 description 4
- 238000003757 reverse transcription PCR Methods 0.000 description 4
- 150000003839 salts Chemical class 0.000 description 4
- 238000000926 separation method Methods 0.000 description 4
- 239000013589 supplement Substances 0.000 description 4
- 238000007399 DNA isolation Methods 0.000 description 3
- 108010014303 DNA-directed DNA polymerase Proteins 0.000 description 3
- 102000016928 DNA-directed DNA polymerase Human genes 0.000 description 3
- 108700005091 Immunoglobulin Genes Proteins 0.000 description 3
- 238000000636 Northern blotting Methods 0.000 description 3
- 108020004711 Nucleic Acid Probes Proteins 0.000 description 3
- 108091034117 Oligonucleotide Proteins 0.000 description 3
- 108090000315 Protein Kinase C Proteins 0.000 description 3
- 102000003923 Protein Kinase C Human genes 0.000 description 3
- 208000015634 Rectal Neoplasms Diseases 0.000 description 3
- 108091028664 Ribonucleotide Proteins 0.000 description 3
- 206010041067 Small cell lung cancer Diseases 0.000 description 3
- 208000005718 Stomach Neoplasms Diseases 0.000 description 3
- 125000000539 amino acid group Chemical group 0.000 description 3
- 230000033228 biological regulation Effects 0.000 description 3
- 210000001124 body fluid Anatomy 0.000 description 3
- 239000010839 body fluid Substances 0.000 description 3
- 239000000872 buffer Substances 0.000 description 3
- 238000011109 contamination Methods 0.000 description 3
- 239000005547 deoxyribonucleotide Substances 0.000 description 3
- 125000002637 deoxyribonucleotide group Chemical group 0.000 description 3
- 238000011161 development Methods 0.000 description 3
- 238000003745 diagnosis Methods 0.000 description 3
- 230000003828 downregulation Effects 0.000 description 3
- 238000002474 experimental method Methods 0.000 description 3
- 238000000338 in vitro Methods 0.000 description 3
- 239000011159 matrix material Substances 0.000 description 3
- 230000007246 mechanism Effects 0.000 description 3
- 239000002853 nucleic acid probe Substances 0.000 description 3
- 238000001558 permutation test Methods 0.000 description 3
- 230000002829 reductive effect Effects 0.000 description 3
- 238000012552 review Methods 0.000 description 3
- 239000002336 ribonucleotide Substances 0.000 description 3
- 125000002652 ribonucleotide group Chemical group 0.000 description 3
- 230000019491 signal transduction Effects 0.000 description 3
- 208000000587 small cell lung carcinoma Diseases 0.000 description 3
- 238000011179 visual inspection Methods 0.000 description 3
- HCAJQHYUCKICQH-VPENINKCSA-N 8-Oxo-7,8-dihydro-2'-deoxyguanosine Chemical compound C1=2NC(N)=NC(=O)C=2NC(=O)N1[C@H]1C[C@H](O)[C@@H](CO)O1 HCAJQHYUCKICQH-VPENINKCSA-N 0.000 description 2
- 208000010507 Adenocarcinoma of Lung Diseases 0.000 description 2
- 239000004475 Arginine Substances 0.000 description 2
- 208000033116 Asbestos intoxication Diseases 0.000 description 2
- 108010004586 Ataxia Telangiectasia Mutated Proteins Proteins 0.000 description 2
- 206010008342 Cervix carcinoma Diseases 0.000 description 2
- 108010043471 Core Binding Factor Alpha 2 Subunit Proteins 0.000 description 2
- 102000053602 DNA Human genes 0.000 description 2
- 108020004414 DNA Proteins 0.000 description 2
- 238000007400 DNA extraction Methods 0.000 description 2
- 108090000626 DNA-directed RNA polymerases Proteins 0.000 description 2
- 102000004163 DNA-directed RNA polymerases Human genes 0.000 description 2
- 238000002965 ELISA Methods 0.000 description 2
- ZHNUHDYFZUAESO-UHFFFAOYSA-N Formamide Chemical compound NC=O ZHNUHDYFZUAESO-UHFFFAOYSA-N 0.000 description 2
- 102000003817 Fos-related antigen 1 Human genes 0.000 description 2
- 108090000123 Fos-related antigen 1 Proteins 0.000 description 2
- 101000707471 Homo sapiens Serine incorporator 3 Proteins 0.000 description 2
- 108091005461 Nucleic proteins Proteins 0.000 description 2
- 206010073310 Occupational exposures Diseases 0.000 description 2
- 238000002123 RNA extraction Methods 0.000 description 2
- 102100025373 Runt-related transcription factor 1 Human genes 0.000 description 2
- 102000005031 SLC6A15 Human genes 0.000 description 2
- 108060007754 SLC6A15 Proteins 0.000 description 2
- 102100026715 Serine/threonine-protein kinase STK11 Human genes 0.000 description 2
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 2
- 102100031027 Transcription activator BRG1 Human genes 0.000 description 2
- 108700025716 Tumor Suppressor Genes Proteins 0.000 description 2
- 102000044209 Tumor Suppressor Genes Human genes 0.000 description 2
- 208000006105 Uterine Cervical Neoplasms Diseases 0.000 description 2
- 102100038965 WAP four-disulfide core domain protein 2 Human genes 0.000 description 2
- 239000012190 activator Substances 0.000 description 2
- ODKSFYDXXFIFQN-UHFFFAOYSA-N arginine Natural products OC(=O)C(N)CCCNC(N)=N ODKSFYDXXFIFQN-UHFFFAOYSA-N 0.000 description 2
- 206010003441 asbestosis Diseases 0.000 description 2
- 238000010805 cDNA synthesis kit Methods 0.000 description 2
- 230000000711 cancerogenic effect Effects 0.000 description 2
- 231100000315 carcinogenic Toxicity 0.000 description 2
- 230000001413 cellular effect Effects 0.000 description 2
- 201000010881 cervical cancer Diseases 0.000 description 2
- 238000010835 comparative analysis Methods 0.000 description 2
- 230000000052 comparative effect Effects 0.000 description 2
- 239000002131 composite material Substances 0.000 description 2
- 238000010219 correlation analysis Methods 0.000 description 2
- 238000002790 cross-validation Methods 0.000 description 2
- 230000003247 decreasing effect Effects 0.000 description 2
- 230000007547 defect Effects 0.000 description 2
- 230000000857 drug effect Effects 0.000 description 2
- 239000000975 dye Substances 0.000 description 2
- 238000013399 early diagnosis Methods 0.000 description 2
- 238000011156 evaluation Methods 0.000 description 2
- 238000010195 expression analysis Methods 0.000 description 2
- 206010017758 gastric cancer Diseases 0.000 description 2
- 238000011223 gene expression profiling Methods 0.000 description 2
- 239000011521 glass Substances 0.000 description 2
- 238000003306 harvesting Methods 0.000 description 2
- 238000007490 hematoxylin and eosin (H&E) staining Methods 0.000 description 2
- 238000011534 incubation Methods 0.000 description 2
- 239000003112 inhibitor Substances 0.000 description 2
- 238000003780 insertion Methods 0.000 description 2
- 230000037431 insertion Effects 0.000 description 2
- 230000010354 integration Effects 0.000 description 2
- 238000002955 isolation Methods 0.000 description 2
- 238000007834 ligase chain reaction Methods 0.000 description 2
- MYWUZJCMWCOHBA-VIFPVBQESA-N methamphetamine Chemical compound CN[C@@H](C)CC1=CC=CC=C1 MYWUZJCMWCOHBA-VIFPVBQESA-N 0.000 description 2
- 230000011987 methylation Effects 0.000 description 2
- 238000007069 methylation reaction Methods 0.000 description 2
- CXKWCBBOMKCUKX-UHFFFAOYSA-M methylene blue Chemical compound [Cl-].C1=CC(N(C)C)=CC2=[S+]C3=CC(N(C)C)=CC=C3N=C21 CXKWCBBOMKCUKX-UHFFFAOYSA-M 0.000 description 2
- 229960000907 methylthioninium chloride Drugs 0.000 description 2
- 231100000675 occupational exposure Toxicity 0.000 description 2
- 230000001151 other effect Effects 0.000 description 2
- 230000002093 peripheral effect Effects 0.000 description 2
- 238000006116 polymerization reaction Methods 0.000 description 2
- 230000004952 protein activity Effects 0.000 description 2
- 238000013441 quality evaluation Methods 0.000 description 2
- 230000005855 radiation Effects 0.000 description 2
- 229910052704 radon Inorganic materials 0.000 description 2
- SYUHGPGVQRZVTB-UHFFFAOYSA-N radon atom Chemical compound [Rn] SYUHGPGVQRZVTB-UHFFFAOYSA-N 0.000 description 2
- 239000007845 reactive nitrogen species Substances 0.000 description 2
- 238000003753 real-time PCR Methods 0.000 description 2
- 206010038038 rectal cancer Diseases 0.000 description 2
- 201000001275 rectum cancer Diseases 0.000 description 2
- 108091008146 restriction endonucleases Proteins 0.000 description 2
- 230000037432 silent mutation Effects 0.000 description 2
- 238000002741 site-directed mutagenesis Methods 0.000 description 2
- 239000011780 sodium chloride Substances 0.000 description 2
- 229910001415 sodium ion Inorganic materials 0.000 description 2
- 239000007787 solid Substances 0.000 description 2
- 241000894007 species Species 0.000 description 2
- 238000007619 statistical method Methods 0.000 description 2
- 201000011549 stomach cancer Diseases 0.000 description 2
- 238000003860 storage Methods 0.000 description 2
- 239000000758 substrate Substances 0.000 description 2
- 208000024891 symptom Diseases 0.000 description 2
- 150000004992 toluidines Chemical class 0.000 description 2
- 238000012549 training Methods 0.000 description 2
- 230000005945 translocation Effects 0.000 description 2
- 210000004881 tumor cell Anatomy 0.000 description 2
- 238000012108 two-stage analysis Methods 0.000 description 2
- 101150082072 14 gene Proteins 0.000 description 1
- JRYMOPZHXMVHTA-DAGMQNCNSA-N 2-amino-7-[(2r,3r,4s,5r)-3,4-dihydroxy-5-(hydroxymethyl)oxolan-2-yl]-1h-pyrrolo[2,3-d]pyrimidin-4-one Chemical compound C1=CC=2C(=O)NC(N)=NC=2N1[C@@H]1O[C@H](CO)[C@@H](O)[C@H]1O JRYMOPZHXMVHTA-DAGMQNCNSA-N 0.000 description 1
- 102000000872 ATM Human genes 0.000 description 1
- 206010068873 Adenosquamous cell carcinoma Diseases 0.000 description 1
- 101150106849 BRG1 gene Proteins 0.000 description 1
- 108010077805 Bacterial Proteins Proteins 0.000 description 1
- 102100037674 Bis(5'-adenosyl)-triphosphatase Human genes 0.000 description 1
- 201000009030 Carcinoma Diseases 0.000 description 1
- 206010008805 Chromosomal abnormalities Diseases 0.000 description 1
- 208000031404 Chromosome Aberrations Diseases 0.000 description 1
- 208000037088 Chromosome Breakage Diseases 0.000 description 1
- 108091026890 Coding region Proteins 0.000 description 1
- 206010009944 Colon cancer Diseases 0.000 description 1
- 208000001333 Colorectal Neoplasms Diseases 0.000 description 1
- 102100032218 Cytokine-inducible SH2-containing protein Human genes 0.000 description 1
- 108020005124 DNA Adducts Proteins 0.000 description 1
- 238000000018 DNA microarray Methods 0.000 description 1
- 230000006820 DNA synthesis Effects 0.000 description 1
- 206010061818 Disease progression Diseases 0.000 description 1
- 208000030453 Drug-Related Side Effects and Adverse reaction Diseases 0.000 description 1
- 102000004190 Enzymes Human genes 0.000 description 1
- 108090000790 Enzymes Proteins 0.000 description 1
- 108700039887 Essential Genes Proteins 0.000 description 1
- 101150099271 FHIT gene Proteins 0.000 description 1
- 206010016654 Fibrosis Diseases 0.000 description 1
- 101001027506 Homo sapiens Bis(5'-adenosyl)-triphosphatase Proteins 0.000 description 1
- 101000943420 Homo sapiens Cytokine-inducible SH2-containing protein Proteins 0.000 description 1
- 101000970385 Homo sapiens Endonuclease III-like protein 1 Proteins 0.000 description 1
- 101000590492 Homo sapiens Nuclear fragile X mental retardation-interacting protein 1 Proteins 0.000 description 1
- 101100476219 Homo sapiens RUNX3 gene Proteins 0.000 description 1
- 101000628562 Homo sapiens Serine/threonine-protein kinase STK11 Proteins 0.000 description 1
- 101000702545 Homo sapiens Transcription activator BRG1 Proteins 0.000 description 1
- 101000777263 Homo sapiens UV radiation resistance-associated gene protein Proteins 0.000 description 1
- 108060003951 Immunoglobulin Proteins 0.000 description 1
- 108010067060 Immunoglobulin Variable Region Proteins 0.000 description 1
- 229930010555 Inosine Natural products 0.000 description 1
- UGQMRVRMYYASKQ-KQYNXXCUSA-N Inosine Chemical compound O[C@@H]1[C@H](O)[C@@H](CO)O[C@H]1N1C2=NC=NC(O)=C2N=C1 UGQMRVRMYYASKQ-KQYNXXCUSA-N 0.000 description 1
- 102100034343 Integrase Human genes 0.000 description 1
- 241000764238 Isis Species 0.000 description 1
- FFEARJCKVFRZRR-BYPYZUCNSA-N L-methionine Chemical compound CSCC[C@H](N)C(O)=O FFEARJCKVFRZRR-BYPYZUCNSA-N 0.000 description 1
- 208000004852 Lung Injury Diseases 0.000 description 1
- 101150033052 MAS5 gene Proteins 0.000 description 1
- 241000940612 Medina Species 0.000 description 1
- 241001465754 Metazoa Species 0.000 description 1
- 241000699670 Mus sp. Species 0.000 description 1
- 241000208125 Nicotiana Species 0.000 description 1
- 235000002637 Nicotiana tabacum Nutrition 0.000 description 1
- 239000000020 Nitrocellulose Substances 0.000 description 1
- 102100032428 Nuclear fragile X mental retardation-interacting protein 1 Human genes 0.000 description 1
- 101710163270 Nuclease Proteins 0.000 description 1
- 239000004677 Nylon Substances 0.000 description 1
- 206010033128 Ovarian cancer Diseases 0.000 description 1
- 206010061535 Ovarian neoplasm Diseases 0.000 description 1
- 238000012408 PCR amplification Methods 0.000 description 1
- 108091093037 Peptide nucleic acid Proteins 0.000 description 1
- 241000139306 Platt Species 0.000 description 1
- 108010066717 Q beta Replicase Proteins 0.000 description 1
- 108010092799 RNA-directed DNA polymerase Proteins 0.000 description 1
- 108020005091 Replication Origin Proteins 0.000 description 1
- 102000006382 Ribonucleases Human genes 0.000 description 1
- 108010083644 Ribonucleases Proteins 0.000 description 1
- 101100344462 Saccharomyces cerevisiae (strain ATCC 204508 / S288c) YDJ1 gene Proteins 0.000 description 1
- 102100031727 Serine incorporator 3 Human genes 0.000 description 1
- 101710181599 Serine/threonine-protein kinase STK11 Proteins 0.000 description 1
- 108020004682 Single-Stranded DNA Proteins 0.000 description 1
- 101150054344 Smarca4 gene Proteins 0.000 description 1
- 238000002105 Southern blotting Methods 0.000 description 1
- 206010070863 Toxicity to various agents Diseases 0.000 description 1
- 102000040945 Transcription factor Human genes 0.000 description 1
- 108091023040 Transcription factor Proteins 0.000 description 1
- 206010069363 Traumatic lung injury Diseases 0.000 description 1
- 102100031275 UV radiation resistance-associated gene protein Human genes 0.000 description 1
- 101150042718 Uvrag gene Proteins 0.000 description 1
- 108091002660 WAP Four-Disulfide Core Domain Protein 2 Proteins 0.000 description 1
- SWPYNTWPIAZGLT-UHFFFAOYSA-N [amino(ethoxy)phosphanyl]oxyethane Chemical compound CCOP(N)OCC SWPYNTWPIAZGLT-UHFFFAOYSA-N 0.000 description 1
- 239000002253 acid Substances 0.000 description 1
- 230000002378 acidificating effect Effects 0.000 description 1
- 150000007513 acids Chemical class 0.000 description 1
- 230000009471 action Effects 0.000 description 1
- 230000002730 additional effect Effects 0.000 description 1
- 108010076723 adducin Proteins 0.000 description 1
- 102000011759 adducin Human genes 0.000 description 1
- 201000008395 adenosquamous carcinoma Diseases 0.000 description 1
- 210000002821 alveolar epithelial cell Anatomy 0.000 description 1
- 238000000137 annealing Methods 0.000 description 1
- 230000004888 barrier function Effects 0.000 description 1
- 238000003766 bioinformatics method Methods 0.000 description 1
- 230000008827 biological function Effects 0.000 description 1
- 230000007321 biological mechanism Effects 0.000 description 1
- 239000000090 biomarker Substances 0.000 description 1
- 238000004364 calculation method Methods 0.000 description 1
- 239000000969 carrier Substances 0.000 description 1
- 230000020411 cell activation Effects 0.000 description 1
- 230000022131 cell cycle Effects 0.000 description 1
- 230000006369 cell cycle progression Effects 0.000 description 1
- 230000030833 cell death Effects 0.000 description 1
- 230000024245 cell differentiation Effects 0.000 description 1
- 239000013592 cell lysate Substances 0.000 description 1
- 238000003759 clinical diagnosis Methods 0.000 description 1
- 238000012790 confirmation Methods 0.000 description 1
- 239000000470 constituent Substances 0.000 description 1
- 230000001276 controlling effect Effects 0.000 description 1
- 238000007796 conventional method Methods 0.000 description 1
- 230000009260 cross reactivity Effects 0.000 description 1
- 231100000599 cytotoxic agent Toxicity 0.000 description 1
- 229940127089 cytotoxic agent Drugs 0.000 description 1
- 239000002254 cytotoxic agent Substances 0.000 description 1
- 230000006378 damage Effects 0.000 description 1
- 238000004925 denaturation Methods 0.000 description 1
- 230000036425 denaturation Effects 0.000 description 1
- 230000001419 dependent effect Effects 0.000 description 1
- 230000000368 destabilizing effect Effects 0.000 description 1
- 230000005750 disease progression Effects 0.000 description 1
- 208000035475 disorder Diseases 0.000 description 1
- 238000009509 drug development Methods 0.000 description 1
- 230000036267 drug metabolism Effects 0.000 description 1
- 238000007877 drug screening Methods 0.000 description 1
- 239000003596 drug target Substances 0.000 description 1
- 239000000428 dust Substances 0.000 description 1
- 238000010218 electron microscopic analysis Methods 0.000 description 1
- 238000001962 electrophoresis Methods 0.000 description 1
- 238000002149 energy-dispersive X-ray emission spectroscopy Methods 0.000 description 1
- 230000007613 environmental effect Effects 0.000 description 1
- 230000004761 fibrosis Effects 0.000 description 1
- 239000012530 fluid Substances 0.000 description 1
- 230000004927 fusion Effects 0.000 description 1
- 238000007429 general method Methods 0.000 description 1
- 230000037442 genomic alteration Effects 0.000 description 1
- 231100000024 genotoxic Toxicity 0.000 description 1
- 230000001738 genotoxic effect Effects 0.000 description 1
- 230000009931 harmful effect Effects 0.000 description 1
- 238000007417 hierarchical cluster analysis Methods 0.000 description 1
- 230000006607 hypermethylation Effects 0.000 description 1
- 238000010191 image analysis Methods 0.000 description 1
- 238000003703 image analysis method Methods 0.000 description 1
- 230000001900 immune effect Effects 0.000 description 1
- 230000008105 immune reaction Effects 0.000 description 1
- 230000028993 immune response Effects 0.000 description 1
- 102000018358 immunoglobulin Human genes 0.000 description 1
- 238000003364 immunohistochemistry Methods 0.000 description 1
- 230000002779 inactivation Effects 0.000 description 1
- 230000002401 inhibitory effect Effects 0.000 description 1
- 230000000977 initiatory effect Effects 0.000 description 1
- 229960003786 inosine Drugs 0.000 description 1
- 230000003993 interaction Effects 0.000 description 1
- 230000003834 intracellular effect Effects 0.000 description 1
- 238000002372 labelling Methods 0.000 description 1
- 208000003849 large cell carcinoma Diseases 0.000 description 1
- 201000003445 large cell neuroendocrine carcinoma Diseases 0.000 description 1
- 208000032839 leukemia Diseases 0.000 description 1
- 210000000265 leukocyte Anatomy 0.000 description 1
- 230000007774 longterm Effects 0.000 description 1
- 201000005249 lung adenocarcinoma Diseases 0.000 description 1
- 230000004758 lung carcinogenesis Effects 0.000 description 1
- 231100000515 lung injury Toxicity 0.000 description 1
- 201000009546 lung large cell carcinoma Diseases 0.000 description 1
- 208000006178 malignant mesothelioma Diseases 0.000 description 1
- 238000000691 measurement method Methods 0.000 description 1
- 238000002844 melting Methods 0.000 description 1
- 230000008018 melting Effects 0.000 description 1
- 210000005033 mesothelial cell Anatomy 0.000 description 1
- 229910052751 metal Inorganic materials 0.000 description 1
- 239000002184 metal Substances 0.000 description 1
- 150000002739 metals Chemical class 0.000 description 1
- 230000031864 metaphase Effects 0.000 description 1
- 229930182817 methionine Natural products 0.000 description 1
- 238000010208 microarray analysis Methods 0.000 description 1
- 238000001393 microlithography Methods 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 239000000178 monomer Substances 0.000 description 1
- 239000003471 mutagenic agent Substances 0.000 description 1
- 231100000707 mutagenic chemical Toxicity 0.000 description 1
- JTSLALYXYSRPGW-UHFFFAOYSA-N n-[5-(4-cyanophenyl)-1h-pyrrolo[2,3-b]pyridin-3-yl]pyridine-3-carboxamide Chemical compound C=1C=CN=CC=1C(=O)NC(C1=C2)=CNC1=NC=C2C1=CC=C(C#N)C=C1 JTSLALYXYSRPGW-UHFFFAOYSA-N 0.000 description 1
- 230000001613 neoplastic effect Effects 0.000 description 1
- 229920001220 nitrocellulos Polymers 0.000 description 1
- 208000002154 non-small cell lung carcinoma Diseases 0.000 description 1
- 238000003499 nucleic acid array Methods 0.000 description 1
- 239000002777 nucleoside Substances 0.000 description 1
- -1 nucleoside triphosphates Chemical class 0.000 description 1
- 229920001778 nylon Polymers 0.000 description 1
- 239000012188 paraffin wax Substances 0.000 description 1
- 230000008506 pathogenesis Effects 0.000 description 1
- 230000007170 pathology Effects 0.000 description 1
- 230000037361 pathway Effects 0.000 description 1
- 210000005259 peripheral blood Anatomy 0.000 description 1
- 239000011886 peripheral blood Substances 0.000 description 1
- 150000004713 phosphodiesters Chemical class 0.000 description 1
- 239000004033 plastic Substances 0.000 description 1
- 229920003023 plastic Polymers 0.000 description 1
- 230000008488 polyadenylation Effects 0.000 description 1
- 230000037452 priming Effects 0.000 description 1
- 230000002685 pulmonary effect Effects 0.000 description 1
- 238000000746 purification Methods 0.000 description 1
- 239000002994 raw material Substances 0.000 description 1
- 239000013074 reference sample Substances 0.000 description 1
- 230000022532 regulation of transcription, DNA-dependent Effects 0.000 description 1
- 230000003014 reinforcing effect Effects 0.000 description 1
- 230000008439 repair process Effects 0.000 description 1
- 230000010076 replication Effects 0.000 description 1
- 230000009919 sequestration Effects 0.000 description 1
- 238000007873 sieving Methods 0.000 description 1
- 229910052604 silicate mineral Inorganic materials 0.000 description 1
- 239000000377 silicon dioxide Substances 0.000 description 1
- 231100000188 sister chromatid exchange Toxicity 0.000 description 1
- 239000007790 solid phase Substances 0.000 description 1
- 230000009870 specific binding Effects 0.000 description 1
- 238000010561 standard procedure Methods 0.000 description 1
- 238000001356 surgical procedure Methods 0.000 description 1
- 230000004083 survival effect Effects 0.000 description 1
- 230000002195 synergetic effect Effects 0.000 description 1
- 238000001308 synthesis method Methods 0.000 description 1
- IBVCSSOEYUMRLC-GABYNLOESA-N texas red-5-dutp Chemical compound O1[C@H](COP(O)(=O)OP(O)(=O)OP(O)(O)=O)[C@@H](O)C[C@@H]1N1C(=O)NC(=O)C(C#CCNS(=O)(=O)C=2C=C(C(C=3C4=CC=5CCCN6CCCC(C=56)=C4OC4=C5C6=[N+](CCC5)CCCC6=CC4=3)=CC=2)S([O-])(=O)=O)=C1 IBVCSSOEYUMRLC-GABYNLOESA-N 0.000 description 1
- 231100000331 toxic Toxicity 0.000 description 1
- 230000002588 toxic effect Effects 0.000 description 1
- 230000005026 transcription initiation Effects 0.000 description 1
- 230000002103 transcriptional effect Effects 0.000 description 1
- 239000001226 triphosphate Substances 0.000 description 1
- 235000011178 triphosphate Nutrition 0.000 description 1
- 208000010576 undifferentiated carcinoma Diseases 0.000 description 1
- 230000003827 upregulation Effects 0.000 description 1
- 238000011144 upstream manufacturing Methods 0.000 description 1
- 238000012795 verification Methods 0.000 description 1
- 238000001262 western blot Methods 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
- C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
- C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
- C12Q1/6886—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/158—Expression markers
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
- Y10T—TECHNICAL SUBJECTS COVERED BY FORMER US CLASSIFICATION
- Y10T436/00—Chemistry: analytical and immunological testing
- Y10T436/14—Heterocyclic carbon compound [i.e., O, S, N, Se, Te, as only ring hetero atom]
- Y10T436/142222—Hetero-O [e.g., ascorbic acid, etc.]
- Y10T436/143333—Saccharide [e.g., DNA, etc.]
Landscapes
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Engineering & Computer Science (AREA)
- Immunology (AREA)
- Pathology (AREA)
- Analytical Chemistry (AREA)
- Zoology (AREA)
- Genetics & Genomics (AREA)
- Wood Science & Technology (AREA)
- Physics & Mathematics (AREA)
- Biotechnology (AREA)
- Microbiology (AREA)
- Molecular Biology (AREA)
- Hospice & Palliative Care (AREA)
- Biophysics (AREA)
- Oncology (AREA)
- Biochemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Engineering & Computer Science (AREA)
- General Health & Medical Sciences (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| FI20065032A FI121236B (fi) | 2006-01-18 | 2006-01-18 | Menetelmä asbestialtistukseen liittyvien keuhkosyöpien tunnistamiseksi |
| PCT/FI2007/050023 WO2007082998A1 (en) | 2006-01-18 | 2007-01-18 | Method of identifying lung cancers associated with asbestos-exposure |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2009523436A true JP2009523436A (ja) | 2009-06-25 |
| JP2009523436A5 JP2009523436A5 (https=) | 2010-01-28 |
Family
ID=35883930
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2008550791A Withdrawn JP2009523436A (ja) | 2006-01-18 | 2007-01-18 | アスベスト被曝に関連した肺癌を同定する方法 |
Country Status (5)
| Country | Link |
|---|---|
| US (1) | US20100279281A1 (https=) |
| EP (1) | EP1977010A4 (https=) |
| JP (1) | JP2009523436A (https=) |
| FI (1) | FI121236B (https=) |
| WO (1) | WO2007082998A1 (https=) |
Families Citing this family (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN108676888B (zh) * | 2018-07-12 | 2022-01-28 | 吉林大学 | 一种肺部恶性肿瘤易感性预测试剂盒及系统 |
Family Cites Families (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5670314A (en) * | 1994-02-22 | 1997-09-23 | Regents Of The University Of California | Genetic alterations that correlate with lung carcinomas |
| IL159482A0 (en) * | 2001-06-22 | 2004-06-01 | Univ Geneve | Method for detecting diseases caused by chromosomal imbalances |
| WO2003020899A2 (en) * | 2001-08-31 | 2003-03-13 | Diadexus, Inc. | Compositions and methods relating to lung specific genes and proteins |
| CA2527680A1 (en) * | 2003-05-30 | 2005-06-02 | Astrazeneca Uk Limited | Markers for responsiveness to an erbb receptor tyrosine kinase inhibitor |
| CA2554818A1 (en) * | 2004-02-09 | 2005-08-25 | Thomas Jefferson University | Diagnosis and treatment of cancers with microrna located in or near cancer-associated chromosomal features |
| AU2006249780A1 (en) * | 2005-05-26 | 2006-11-30 | The Johns Hopkins University | Compositions and methods for the treatment or prevention of chemoresistant neoplasia |
-
2006
- 2006-01-18 FI FI20065032A patent/FI121236B/fi not_active IP Right Cessation
-
2007
- 2007-01-18 WO PCT/FI2007/050023 patent/WO2007082998A1/en not_active Ceased
- 2007-01-18 US US12/161,003 patent/US20100279281A1/en not_active Abandoned
- 2007-01-18 EP EP07700288A patent/EP1977010A4/en not_active Withdrawn
- 2007-01-18 JP JP2008550791A patent/JP2009523436A/ja not_active Withdrawn
Also Published As
| Publication number | Publication date |
|---|---|
| EP1977010A4 (en) | 2009-07-15 |
| WO2007082998A1 (en) | 2007-07-26 |
| US20100279281A1 (en) | 2010-11-04 |
| FI20065032A0 (fi) | 2006-01-18 |
| FI121236B (fi) | 2010-08-31 |
| FI20065032L (fi) | 2007-07-19 |
| EP1977010A1 (en) | 2008-10-08 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP7512278B2 (ja) | 肺腫瘍の検出におけるメチル化ｄｎａ、ｒｎａ、及びタンパク質の特性決定 | |
| JP6700333B2 (ja) | ヘテロ接合性の消失（ｌｏｓｓ ｏｆ ｈｅｔｅｒｏｚｙｇｏｓｉｔｙ）を評価するための方法および材料 | |
| JP4938672B2 (ja) | ｐ５３の状態と遺伝子発現プロファイルとの関連性に基づき、癌を分類し、予後を予測し、そして診断する方法、システム、およびアレイ | |
| JP5486718B2 (ja) | 結腸直腸癌の予後のための遺伝子発現マーカー | |
| JP2008521412A (ja) | 肺癌予後判定手段 | |
| KR20080065476A (ko) | 폐암 환자 또는 폐암 치료를 받은 폐암 환자에 대한 폐암재발의 위험을 예측하는 방법, 폐암 환자 또는 폐암 치료를받은 환자의 폐암 재발 위험성에 대한 보고서를 작성하는방법, 그에 의하여 작성된 보고서, 폐암 환자 또는 폐암치료를 받은 폐암 환자의 폐암 재발 위험을 진단하기 위한조성물, 키트 및 마이크로어레이 | |
| US20150292033A1 (en) | Method of determining cancer prognosis | |
| EP1940860A4 (en) | METHOD AND COMPOSITIONS FOR IDENTIFYING BIOLOGICAL MARKERS BENEFICIAL FOR DIAGNOSIS AND / OR TREATMENT OF BIOLOGICAL CONDITIONS | |
| Lin et al. | Lung cancer transcriptomes refined with laser capture microdissection | |
| US20250137066A1 (en) | Compostions and methods for diagnosing lung cancers using gene expression profiles | |
| Beer et al. | Polymorphisms of GSTP1 and related genes and prostate cancer risk | |
| Chen et al. | Genetic variants of MGMT, RHPN 2, and FAM 49A contributed to susceptibility of nonsyndromic orofacial clefts in a Chinese population | |
| US10087489B2 (en) | Biomarkers and uses thereof in prognosis and treatment strategies for right-side colon cancer disease and left-side colon cancer disease | |
| EP1497463A1 (en) | Methods to predict patient responsiveness to tyrosine kinase inhibitors | |
| JP2009523436A (ja) | アスベスト被曝に関連した肺癌を同定する方法 | |
| JP6470044B2 (ja) | がんに対する免疫療法の有効性の予測方法 | |
| Class et al. | Patent application title: METHOD OF IDENTIFYING LUNG CANCERS ASSOCIATED WITH ASBESTOS-EXPOSURE Inventors: Sisko Anttila (Espoo, FI) Sakari Knuutila (Espoo, FI) Jaakko Hollmen (Espoo, FI) Salla Ruosaari (Espoo, FI) Harriet Wikman-Kocher (Hamburg, DK) Penny Nymark (Helsinki, FI) Assignees: Licentia Ltd | |
| Hemmati et al. | Investigating the Association of rs4962416 and rs6465657 with Prostate Adenocarcinoma in the Iranian Population | |
| CN116377053A (zh) | 冠状动脉扩张症的诊断生物标志物及其应用 | |
| WO2024059649A1 (en) | Dna methylation signature of retinoblastoma | |
| WO2021061623A1 (en) | Methods for predicting aml outcome | |
| Potluri | Improving DNA quality using FFPE tissues for Array Comparative Genomic Hybridization to find Single Nucleotide Polymorphisms (SNPs) in Melanoma | |
| Pukonen | Gene mapping for type 1 diabetes using a high density genotyping array platform |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20091201 |
|
| A621 | Written request for application examination |
Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20091201 |
|
| A761 | Written withdrawal of application |
Free format text: JAPANESE INTERMEDIATE CODE: A761 Effective date: 20101124 |
|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A821 Effective date: 20101124 |